Profile: AMAG Pharmaceuticals Inc (AMAG.OQ)
18 Aug 2017
AMAG Pharmaceuticals, Inc., incorporated on November 9, 1981, is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. The Company has a portfolio of products and services with a focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol) for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women.
The Company's product, Makena, is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth. Makena is an intramuscular injection administered weekly by a healthcare professional at a dose of approximately 250 milligrams with treatment beginning between 16 weeks and 20 weeks and six days of gestation and continuing until 36 weeks and six days of gestation or delivery. Makena is a progestin whose active ingredient is hydroxyprogesterone caproate (HPC), which is a synthetic chemical structurally related to progesterone. The Company sells Makena primarily to specialty pharmacies, specialty distributors, home infusion companies and pharmacies, which sell Makena to healthcare providers, hospitals, government agencies and integrated delivery systems.
CBR is a private newborn stem cell bank that offers pregnant women and their families the ability to preserve their newborns' umbilical cord blood and cord tissue for future use (the CBR Services). The CBR Services include the collection, processing and storage of both umbilical cord blood and cord tissue. Feraheme is an IV iron replacement therapeutic agent for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD). Feraheme is in a Phase III clinical trial for the treatment of patients with a history of unsatisfactory oral iron therapy or in whom oral iron cannot be used. The Company sells Feraheme to authorized wholesalers and specialty distributors, and Feraheme is in turn sold to healthcare providers administering Feraheme primarily within nephrology clinics, and hematology and oncology centers and hospitals. The MuGard Mucoadhesive Oral Wound Rinse product is used for the management of oral mucositis/stomatitis and various types of oral wounds.
The Company competes with PerkinElmer, Inc., Cryo-Cell International, Inc., StemCyte, Fresenius Medical Care North America, Luitpold Pharmaceuticals, Inc., Sanofi-Aventis U.S. LLC, Teva Pharmaceuticals, Inc. and Allergan, Inc.
AMAG Pharmaceuticals Inc
1100 Winter St
WALTHAM MA 02451-1427
Company Web Links
- BRIEF-Amag Pharmaceuticals Q2 loss per share $0.40
- BRIEF-Amag completes feraheme FDA submission for the treatment of all adult patients with iron deficiency anemia
- BRIEF-Amag Pharmaceuticals announces commercial availability of Intrarosa (prasterone) at U.S. pharmacies
- BRIEF-Amag reports U.S. FDA acceptance of supplemental new drug application for Makena
- BRIEF-Camber Capital Management LLC reports 7.13 pct passive stake in AMAG Pharmaceuticals